FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060485000> ?p ?o ?g. }

• W2060485000 endingPage "77" @default.
• W2060485000 startingPage "73" @default.
• W2060485000 abstract "There are no generally effective disease-modifying drugs for progressive forms of multiple sclerosis (MS). Some MS centres use cyclophosphamide (CYC) in secondary progressive (SP) forms of MS, especially after interferon beta-1b (INFbeta-1b) treatment failure. Moreover, there are currently no approved drugs for primary progressive (PP) MS. Using the collected data of patients with progressive MS, we studied clinical patterns that predicted a good response to CYC treatment. Secondly, we compared the therapeutic response of SPMS and PPMS patients to the treatment. Data from 490 MS patients were collected. All patients presented an SP (n = 362) or PP (n = 128) form of the disease and 476 had been treated for at least one year with a monthly pulse of CYC associated with methylprednisolone (MP). CYC treatment was justified because of at least a 1-point worsening on the Expanded Disability Status Scale (EDSS) during the previous year. The EDSS score was assessed at baseline and after 6 months (M6) and 12 months (M12) of treatment. After 12 months of CYC treatment, 78.6% of SPMS and 73.5% of PPMS patients had stabilised or had an improved EDSS score. Response to CYC was not significantly different in the two progressive forms of MS. Twenty-two patients presented noticeable drug side effects, one of whom withdrew from the treatment due to intolerance. Patients with an improved EDSS at M12 had a shorter mean progressive time course (5.1 years) than patients who stabilised or worsened (7.1 years) (p = 0.02). We also observed that poor responders at M6 were also poor responders at M12 (p < 0.001). This large cohort study showed that CYC treatment was well tolerated and suggested that a better response occurred in cases with a short progressive time course. We did not find any difference in treatment response between the two progressive forms of MS. To date, no treatment is approved for PPMS and we therefore propose a trial to test the use of CYC treatment early in the course of the disease in PPMS patients with disability progression." @default.
• W2060485000 created "2016-06-24" @default.
• W2060485000 creator A5001219883 @default.
• W2060485000 creator A5005205127 @default.
• W2060485000 creator A5025462803 @default.
• W2060485000 creator A5038662347 @default.
• W2060485000 creator A5044860949 @default.
• W2060485000 creator A5054006135 @default.
• W2060485000 creator A5064932437 @default.
• W2060485000 creator A5069898068 @default.
• W2060485000 creator A5070134975 @default.
• W2060485000 creator A5079607840 @default.
• W2060485000 date "2004-03-01" @default.
• W2060485000 modified "2023-10-17" @default.
• W2060485000 title "Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients" @default.
• W2060485000 cites W1981668078 @default.
• W2060485000 cites W1998455368 @default.
• W2060485000 cites W2025765189 @default.
• W2060485000 cites W2036346342 @default.
• W2060485000 cites W2051298001 @default.
• W2060485000 cites W2051609512 @default.
• W2060485000 cites W2070656641 @default.
• W2060485000 cites W2079367120 @default.
• W2060485000 cites W2097669496 @default.
• W2060485000 cites W2103285247 @default.
• W2060485000 cites W2110249745 @default.
• W2060485000 cites W2112165124 @default.
• W2060485000 cites W2119172537 @default.
• W2060485000 cites W2130355701 @default.
• W2060485000 cites W2147603018 @default.
• W2060485000 cites W2158338004 @default.
• W2060485000 cites W2189829250 @default.
• W2060485000 cites W4240901768 @default.
• W2060485000 doi "https://doi.org/10.1016/j.jns.2003.11.004" @default.
• W2060485000 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14759636" @default.
• W2060485000 hasPublicationYear "2004" @default.
• W2060485000 type Work @default.
• W2060485000 sameAs 2060485000 @default.
• W2060485000 citedByCount "59" @default.
• W2060485000 countsByYear W20604850002012 @default.
• W2060485000 countsByYear W20604850002013 @default.
• W2060485000 countsByYear W20604850002014 @default.
• W2060485000 countsByYear W20604850002015 @default.
• W2060485000 countsByYear W20604850002016 @default.
• W2060485000 countsByYear W20604850002017 @default.
• W2060485000 countsByYear W20604850002019 @default.
• W2060485000 countsByYear W20604850002020 @default.
• W2060485000 countsByYear W20604850002022 @default.
• W2060485000 crossrefType "journal-article" @default.
• W2060485000 hasAuthorship W2060485000A5001219883 @default.
• W2060485000 hasAuthorship W2060485000A5005205127 @default.
• W2060485000 hasAuthorship W2060485000A5025462803 @default.
• W2060485000 hasAuthorship W2060485000A5038662347 @default.
• W2060485000 hasAuthorship W2060485000A5044860949 @default.
• W2060485000 hasAuthorship W2060485000A5054006135 @default.
• W2060485000 hasAuthorship W2060485000A5064932437 @default.
• W2060485000 hasAuthorship W2060485000A5069898068 @default.
• W2060485000 hasAuthorship W2060485000A5070134975 @default.
• W2060485000 hasAuthorship W2060485000A5079607840 @default.
• W2060485000 hasConcept C126322002 @default.
• W2060485000 hasConcept C141071460 @default.
• W2060485000 hasConcept C203014093 @default.
• W2060485000 hasConcept C2776694085 @default.
• W2060485000 hasConcept C2776755627 @default.
• W2060485000 hasConcept C2778822529 @default.
• W2060485000 hasConcept C2779134260 @default.
• W2060485000 hasConcept C2780372218 @default.
• W2060485000 hasConcept C2780640218 @default.
• W2060485000 hasConcept C2780892749 @default.
• W2060485000 hasConcept C71924100 @default.
• W2060485000 hasConcept C72563966 @default.
• W2060485000 hasConcept C90924648 @default.
• W2060485000 hasConceptScore W2060485000C126322002 @default.
• W2060485000 hasConceptScore W2060485000C141071460 @default.
• W2060485000 hasConceptScore W2060485000C203014093 @default.
• W2060485000 hasConceptScore W2060485000C2776694085 @default.
• W2060485000 hasConceptScore W2060485000C2776755627 @default.
• W2060485000 hasConceptScore W2060485000C2778822529 @default.
• W2060485000 hasConceptScore W2060485000C2779134260 @default.
• W2060485000 hasConceptScore W2060485000C2780372218 @default.
• W2060485000 hasConceptScore W2060485000C2780640218 @default.
• W2060485000 hasConceptScore W2060485000C2780892749 @default.
• W2060485000 hasConceptScore W2060485000C71924100 @default.
• W2060485000 hasConceptScore W2060485000C72563966 @default.
• W2060485000 hasConceptScore W2060485000C90924648 @default.
• W2060485000 hasIssue "1-2" @default.
• W2060485000 hasLocation W20604850001 @default.
• W2060485000 hasLocation W20604850002 @default.
• W2060485000 hasOpenAccess W2060485000 @default.
• W2060485000 hasPrimaryLocation W20604850001 @default.
• W2060485000 hasRelatedWork W2048236870 @default.
• W2060485000 hasRelatedWork W2102575453 @default.
• W2060485000 hasRelatedWork W2106785302 @default.
• W2060485000 hasRelatedWork W2108119941 @default.
• W2060485000 hasRelatedWork W2343444777 @default.
• W2060485000 hasRelatedWork W2393448476 @default.
• W2060485000 hasRelatedWork W2399453054 @default.
• W2060485000 hasRelatedWork W2406589399 @default.

• next